A2i Therapeutics

Novel Small-molecule Immuno-oncology Agents

Active Seed Startup Founded 2020-11

A2i Therapeutics is developing novel small-molecule immuno-oncology agents. The company was formed as a joint venture between FutuRx, an Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies, and Atomwise, a US-based company using artificial intelligence for small-molecule drug discovery. The partnership will leve…